Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Genitourinary 1

Conditions

Wilms Tumor 6Ovarian Neoplasms 6Neuroblastoma 5Testicular Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Kidney Neoplasms 4Astrocytoma 4Optic Nerve Glioma 3Oligodendroglioma 3Glioma 3Familial ependymoma 3Choroid Plexus Neoplasms 3Central Nervous System Neoplasms 3Testicular Germ Cell Tumor 2Teratoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Ovarian Germ Cell Cancer 2Neoplasms 2Liver Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1

Interventions

cixutumumab 1Thiotepa 1Temozolomide 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Erlotinib Hydrochloride 1Busulfan 1Bone Marrow Transplantation 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors × Temozolomide × Genitourinary × Clear all
NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

Phase 2 Withdrawn
CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡